guiding you onto the right path

Latest Jobs

Purpose: Acting as the key interface with clients over projects, manages the timely delivery of project outputs in line with client expectations. Dev...
Purpose: Manages the delivery of client project(s), ensuring delivery of the project in line with client objectives and expectations as well as proje...

SENIOR PRINCIPAL (Strategy Group)

As a Senior Principal, you will work directly with clients to deliver projects addressing strategic issues. You will have responsibility for business development, client relationship development, thought leadership, mentoring, and ensuring delivery of high levels of client satisfaction by:

 

  • Operating as a member of the Global Leadership Team, providing leadership to globally and locally
  • Meeting or exceeds assigned revenue targets by developing and delivering insightful, value-added proposals that address complex client issues.
  • Generating leads and leading proposal development to ensure actionable, on-target and timely proposals are provided to clients.
  • Seeking out and identifying new revenue opportunities at existing and potential clients
  • Selling projects and delivering the Business Development target as both Principal in charge and bid team member
  • Developing and/or elevating new business opportunities through the identification of follow-on work and new leads.
  • Owning client engagements with responsibility for client satisfaction and delivering high levels of quality/added value
  • Following-up with client after project deliverable have been completed to ensure client satisfaction.
  • Providing direction, advice and intellectual leadership to clients and delivery teams.
  • Playing a significant role on account planning and strategy with  sales team.
  • Contributing to the enhanced awareness of Consulting in the market place, e.g. through speaking engagements, client meetings, publications
  • Mentoring, coaching and sharing subject matter expertise with others to help develop individuals and our capabilities to deliver world-class solutions for clients
  • Providing direction to our teams to ensure the development of client reports and presentations
  • Leading thought leadership and firm building initiatives
  • Remaining current on industry, client and competitive trends and directions in order to anticipate and identify new business challenges and issues at assigned clients.

 

Senior Principal should have:

 

  • Demonstrated strong leadership skills within a global organization
  • Strong capability in managing projects and juggling priorities so that deadlines are met while retaining consistently high quality outcomes
  • Well-developed written and verbal communication skills including presentations, chairing meetings, workshop facilitation, business and report writing
  • Track record of ability to sell high quality, high value projects to clients
  • Strong capability in managing projects and juggling priorities so that deadlines are met while retaining consistently high quality outcomes
  • Ability to drive Business Development independently
  • Experience of working in sizable/ multi-disciplined teams and supervising staff
  • Experience of developing credible relationships with executives in the pharmaceutical/healthcare industry
  • Excellent interpersonal skills and ability to work effectively with others in and across the organization to accomplish team goals
  • Intensive experience leading, managing, and developing people
  • Broad understand of pharmaceutical industry
  • Knowledge of key issues and current developments in the pharmaceutical and healthcare industries
  • Thorough knowledge of consulting methodologies, tools and techniques

 

In addition to the skills and experience above, candidates interested in joining IMS Consulting Group as a Senior Principal should have:

 

  • A strong academic track record including minimum Bachelor’s degree or equivalent, relevant graduate degree preferred (further personal/industry qualifications are valued but are not essential)
  • At least 12 years professional experience in consulting, pharmaceutical and healthcare industry with evidence of career progression
  • Demonstrable experience in and commitment to the life sciences and/or healthcare industries
  • A strong track record of management, leadership and people development
  • A willingness and ability to travel to client locations
  • Fluency in English (spoken and written)
  • Right to live and work in the recruiting country

 

Job Type:
Permanent
Experience:
Bachelors Degree
Location:
London
Sector:
Commercial
Salary:
£Negotiable
Ref:
104

How to apply

Apply Now

Latest News

Fri, 25 Apr 2025 10:00:00 +0200
Chemists have confirmed a 67-year-old theory about vitamin B1 by stabilizing a reactive molecule in water - a feat long thought impossible. The discovery not only solves a biochemical mystery, but also opens the door to greener, more efficient ways of making pharmaceuticals.

The molecule in question is a carbene, a type of carbon atom with only six valence electrons. Generally, carbon is stable with eight electrons around it. With only six electrons, it is chemically unstable and highly reactive.

Thu, 24 Apr 2025 10:00:00 +0200
Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of the immune system, which then go to work to clear an infection. A new study from Scripps Research explores the factors that influence how effectively antibodies engage specific immune cells.

Their results, described April 22, 2025 in Cell Reports, indicate that a higher ratio of antibodies to viral protein - in this case, a part of HIV - better engages two specific types of immune cells.

Wed, 23 Apr 2025 10:00:00 +0200
BayerBlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, announced the publication of the 18-month data from its Phase 1 exPDite clinical trial for bemdaneprocel in the journal Nature.

"The concept of "rebuilding" brain networks that have been lost to disease is compelling," said Claire Henchcliffe, MD, chair of the UC Irvine School of Medicine's Department of Neurology at the University of California, Irvine and one of the study's Principal Investigators,

Tue, 22 Apr 2025 10:00:00 +0200
When the immune system does not function properly, individuals become more susceptible to infections caused by viruses, bacteria, or fungi. Researchers from Radboud university medical center have demonstrated that an existing drug can revive immune cells that are not functioning correctly. These findings provide leads for further research in patients admitted to the intensive care unit (ICU) with sepsis.
Mon, 21 Apr 2025 10:00:00 +0200
A common pinworm medication may stop and reverse cancer growth in Merkel cell carcinoma, an aggressive form of skin cancer, according to research led by University of Arizona Cancer Center researchers and published in the Journal of Clinical Investigation.

Merkel cell carcinoma is a rare but fast-growing neuroendocrine cancer that is three to five times more likely than melanoma to be deadly.

Fri, 18 Apr 2025 10:00:00 +0200
While organoids aim to mimic human organs, the liver's repertoire of complex functions - and thus the energy it needs to operate - have made it challenging for researchers to grow organoids that proliferate and fully function, says Sato. When prioritizing growth and survival in laboratory settings, hepatocytes, the liver's main cells, eventually transformed into cells resembling cholangiocytes, which line the bile duct. Hepatocyte functions only lasted 1-2 weeks at most.
Thu, 17 Apr 2025 10:00:00 +0200
A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of Alzheimer’s disease and related dementias in patients with Type 2 diabetes.

In research published in JAMA Neurology on April 7, UF researchers studied Medicare claims data of older adults with Type 2 diabetes to assess the association among glucagon-like peptide-1 receptor agonists, or GLP-1RAs, sodium-glucose cotransporter-2 inhibitors, or SGLT2is, and the risk of Alzheimer's disease and related dementias.

Wed, 16 Apr 2025 10:00:00 +0200
A stem cell-based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson's disease, according to results from a phase 1 clinical trial reported in Nature.

The treatment involved creating nerve cells (neurons) derived from embryonic stem cells and transplanting them into the brains of 12 Parkinson's patients.

Tue, 15 Apr 2025 10:00:00 +0200
University of California, Davis researchers have developed a new, neuroplasticity-promoting drug closely related to LSD that harnesses the psychedelic's therapeutic power with reduced hallucinogenic potential.

The research, published in Proceedings of the National Academy of Sciences, highlights the new drug's potential as a treatment option for conditions like schizophrenia, where psychedelics are not prescribed for safety reasons.

Mon, 14 Apr 2025 10:00:00 +0200
Is sauerkraut more than just a tangy topping? A new University of California, Davis, study published in Applied and Environmental Microbiology suggests that the fermented cabbage could help protect your gut, which is an essential part of overall health, supporting digestion and protecting against illness.

Authors Maria Marco, professor with the Department of Food Science and Technology, and Lei Wei, a postdoctoral researcher in Marco's lab, looked at what happens during fermentation - specifically, how the metabolites in sauerkraut compared to those in raw cabbage.

Fri, 11 Apr 2025 10:00:00 +0200
Tim-3 is an immune checkpoint molecule involved in immunity and inflammation recently linked to late-onset Alzheimer's disease (AD), but its role in the brain was unknown until now. In a paper published in Nature, researchers from Mass General Brigham used preclinical models to uncover Tim-3's role in microglia, the brain's resident immune cells, and have identified it as a promising therapeutic target for Alzheimer's disease.
Thu, 10 Apr 2025 10:00:00 +0200
Chinese scientists have revealed a hidden metabolic partnership between breast cancer cells and immune cells that drives aggressive tumor behavior and resistance to immunotherapies. The study sheds light on how tumor cells exploit the amino acid arginine to both fuel their growth and evade the immune system.

The research was led by Prof. HU Hai, who holds dual appointments as professor at the Hangzhou Institute of Medicine (HIM) of the Chinese Academy of Sciences (CAS), and Chief Physician at Zhejiang Cancer Hospital, in collaboration with Prof. LUO Manli from Sun Yat-Sen University and Prof. LI Hongde from HIM.

Wed, 09 Apr 2025 10:00:00 +0200
Meeting the unmet need for a vaccine is the top priority for researchers studying Lyme disease, which infects about 476,000 people in the U.S. each year and can come with severe complications such as ongoing fatigue and joint issues. Vaccine developers have come close to success, but no human vaccine has yet been commercially viable.

After decades of trial and error, a promising new target is emerging - the Lyme bacterial protein CspZ, which the bacteria use to evade detection from the body's immune system.

Tue, 08 Apr 2025 10:00:00 +0200
A significant discovery has identified a missing "gatekeeper" protein as the root cause of dry mouth in Sjögren's syndrome - a finding that could change the way the disease is treated. Researchers pinpointed tricellulin, a protein that helps seal the junctions between saliva gland cells, as the key factor. When inflammation damages tricellulin, saliva production stops and harmful substances leak through.
Mon, 07 Apr 2025 10:00:00 +0200
Every year, millions of people around the world suffer ischemic strokes that block blood flow to a region of the brain.

Restoring blood flow rapidly is decisive and can save lives. But paradoxically, it can also lead to further damage to the blood vessels in the brain.

Fri, 04 Apr 2025 10:00:00 +0200
Gene therapy, a technique that is revolutionizing the treatment of multiple genetic conditions, including eye and muscle diseases and blood disorders, requires efficient and specific delivery of the genetic material to the tissue and cell type of interest. To help improve gene therapy, a multidisciplinary team led by researchers at Baylor College of Medicine, the Jackson Laboratory and the University of Massachusetts Medical School has generated a comprehensive atlas that researchers can use to select the most effective viral vehicle for their target organ.
Thu, 03 Apr 2025 10:00:00 +0200
PfizerPfizer Inc. (NYSE: PFE) announced that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the company's bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age. This expands the previous authorization for individuals aged 60 and older, and ABRYSVO now offers in the EU the broadest RSV vaccine indication, which includes:
Wed, 02 Apr 2025 10:00:00 +0200
A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly blood cancer with a five-year survival rate of just 30%, according to the National Cancer Institute. Their study, published in Cell Stem Cell in February, highlights the crucial role of a protein called paraspeckle component 1 (PSPC1) in the progression of AML.
Tue, 01 Apr 2025 10:00:00 +0200
People with low levels of low-density lipoprotein cholesterol (LDL-C) in their blood have a lower risk of dementia, including lower risk of Alzheimer's disease related dementia, shows a study published online today in the Journal of Neurology Neurosurgery & Psychiatry.

Use of statins conveyed an additional protective effect for people with low LDL-C, specifically those with blood levels less than 1.8 mmol/L (<70 mg/dL), reducing their risk of dementia even further.

Mon, 31 Mar 2025 10:00:00 +0200
Researchers develop innovative phospholipids that improve the functional delivery of mRNA via lipid nanoparticles, paving the way for advanced therapeutic applications.

A groundbreaking study conducted by researchers at Hokkaido University has unveiled a novel class of zwitterionic phospholipids capable of significantly enhancing the functional delivery of mRNA. The study was published in the Advanced Science.

Upload Your CV

Need help finding that new job? Leave your details with us and request a call back from one of our consultants.

Submit A Vacancy

Looking to expand? Or a vacancy has become available in your business then let us know and we can find the right person for you